Cystathionine beta-synthase (CBS)-deficient homocystinuria (HCU) is the most common inborn error of sulfur amino acid metabolism. The pyridoxine non-responsive form of the disease manifests itself by massively increasing plasma and tissue concentrations of homocysteine, a toxic intermediate of methionine metabolism that is thought to be the major cause of clinical complications including skeletal deformities, connective tissue defects, thromboembolism and cognitive impairment. The current standard of care involves significant dietary interventions that, despite being effective, often adversely affect quality of life of HCU patients, leading to poor adherence to therapy and inadequate biochemical control with clinical complications. In recent years, the unmet need for better therapeutic options has resulted in development of novel enzyme and gene therapies and exploration of pharmacological approaches to rescue CBS folding defects caused by missense pathogenic mutations. Here, we review scientific evidence and current state of affairs in development of recent approaches to treat HCU.

Department of Pediatrics and Inherited Metabolic Disorders Charles University 1st Faculty of Medicine Prague Czech Republic

Department of Pediatrics and Inherited Metabolic Disorders General University Hospital Prague Prague Czech Republic

Department of Pharmacology University of Fribourg Faculty of Science and Medicine Fribourg Switzerland

Molecular Therapeutics Program Fox Chase Cancer Center Philadelphia Pennsylvania USA

Zobrazit více v PubMed

Alcaide P, Krijt J, Ruiz-Sala P, Jesina P, Ugarte M, Kozich V, & Merinero B (2015). Enzymatic diagnosis of homocystinuria by determination of cystathionine-ss-synthase activity in plasma using LC-MS/MS. Clin Chim Acta, 438, 261–265. 10.1016/j.cca.2014.09.009 PubMed DOI

Alexander SP, Fabbro D, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Southan C, Davies JA, Boison D, Burns KE, Dessauer C, Gertsch J, Helsby NA, Izzo AA, Koesling D, … Wong SS (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes. Br J Pharmacol, 178 Suppl 1, S313–S411. 10.1111/bph.15542 PubMed DOI

Barber GW, & Spaeth GL (1967). Pyridoxine therapy in homocystinuria. Lancet, 1, 337.

Barber GW, & Spaeth GL (1969). The successful treatment of homocystinuria with pyridoxine. Journal of Pediatrics, 75, 463–478. PubMed

Bernier V, Lagace M, Bichet DG, & Bouvier M (2004). Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab, 15(5), 222–228. 10.1016/j.tem.2004.05.003 PubMed DOI

Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, & Mukherjee P (2013). Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One, 8(11), e79167. 10.1371/journal.pone.0079167 PubMed DOI PMC

Bolen DW, & Rose GD (2008). Structure and energetics of the hydrogen-bonded backbone in protein folding. Annu Rev Biochem, 77, 339–362. 10.1146/annurev.biochem.77.061306.131357 PubMed DOI

Bublil EM, & Majtan T (2020). Classical homocystinuria: From cystathionine beta-synthase deficiency to novel enzyme therapies. Biochimie, 173, 48–56. 10.1016/j.biochi.2019.12.007 PubMed DOI

Bublil EM, Majtan T, Park I, Carrillo RS, Hulkova H, Krijt J, Kozich V, & Kraus JP (2016). Enzyme replacement with PEGylated cystathionine beta-synthase ameliorates homocystinuria in murine model. J Clin Invest, 126(6), 2372–2384. 10.1172/JCI85396 PubMed DOI PMC

Carson NAJ, & Carre IJ (1969). Treatment of homocystinuria with pyridoxine: A preliminary study. Archives of Disease in Childhood, 44, 387–392. PubMed PMC

Carson NAJ, Cusworth DC, Dent CE, Field CMB, Neill DW, & Westall RG (1963). Homocystinuria: A new inborn error of metabolism associated with mental deficiency. Archives of Disease in Childhood, 38, 425–436. PubMed PMC

Chen X, Wang L, Fazlieva R, & Kruger WD (2006). Contrasting behaviors of mutant cystathionine beta-synthase enzymes associated with pyridoxine response. Hum Mutat, 27(5), 474–482. 10.1002/humu.20320 PubMed DOI

Clopath P, Smith VC, & McCully KS (1976). Growth promotion by homocysteic acid. Science, 192, 372–374. PubMed

Cramer SL, Saha A, Liu J, Tadi S, Tiziani S, Yan W, Triplett K, Lamb C, Alters SE, Rowlinson S, Zhang YJ, Keating MJ, Huang P, DiGiovanni J, Georgiou G, & Stone E (2017). Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nat Med, 23(1), 120–127. 10.1038/nm.4232 PubMed DOI PMC

Daige C, Wiggins J, Ferrati S, Priddy L, Van Cleef J, Enzler D, Campbell J, Agnello G, & Rowlinson S (2020). Development of a novel human engineered enzyme (ACN00177) for the treatment of homocystinuria. American Society of Human Genetics Annual Meeting, virtual.

Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD, Heistad DD, Faraci FM, & Lentz SR (2001). Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ Res, 88(11), 1203–1209. http://www.ncbi.nlm.nih.gov/pubmed/11397788 PubMed

DePristo MA, Weinreich DM, & Hartl DL (2005). Missense meanderings in sequence space: a biophysical view of protein evolution. Nat Rev Genet, 6(9), 678–687. 10.1038/nrg1672 PubMed DOI

Druzhyna N, Szczesny B, Olah G, Modis K, Asimakopoulou A, Pavlidou A, Szoleczky P, Gero D, Yanagi K, Toro G, Lopez-Garcia I, Myrianthopoulos V, Mikros E, Zatarain JR, Chao C, Papapetropoulos A, Hellmich MR, & Szabo C (2016). Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine beta-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer. Pharmacol Res, 113(Pt A), 18–37. 10.1016/j.phrs.2016.08.016 PubMed DOI PMC

Dufour E, Lee HO, Gupta S, Meyzaud A, Horand F, Scheer A, & Kruger WD (2017). Erymethionase, methionase entrapped in red blood cells: An innovative treatment approach for classical homocystinuria. 13th Innternational Congress of Inborn Errors of Metabolism, Rio de Janeiro, Brazil.

Folbergrova J (1974). Energy metabolism of mouse cerebral cortex during homocysteine convulsions. Brain Research, 81, 443–454. PubMed

Gay F, Aguera K, Senechal K, Tainturier A, Berlier W, Maucort-Boulch D, Honnorat J, Horand F, Godfrin Y, & Bourgeaux V (2017). Methionine tumor starvation by erythrocyte-encapsulated methionine gamma-lyase activity controlled with per os vitamin B6. Cancer Med, 6(6), 1437–1452. 10.1002/cam4.1086 PubMed DOI PMC

Grieco AJ (1977). Homocystinuria: pathogenetic mechanisms. Am J Med Sci, 273(2), 120–132. https://www.ncbi.nlm.nih.gov/pubmed/324277 PubMed

Gupta S, Gallego-Villar L, Wang L, Lee HO, Nasrallah G, Al-Dewik N, Haberle J, Thony B, Blom HJ, Ben-Omran T, & Kruger WD (2019). Analysis of the Qatari R336C cystathionine beta-synthase protein in mice. J Inherit Metab Dis, 42(5), 831–838. 10.1002/jimd.12140 PubMed DOI PMC

Gupta S, Kelow S, Wang L, Andrake MD, Dunbrack RL Jr., & Kruger WD (2018). Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine beta-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem, 293(36), 13921–13931. 10.1074/jbc.RA118.002164 PubMed DOI PMC

Gupta S, Melnyk SB, & Kruger WD (2014). Cystathionine beta-synthase-deficient mice thrive on a low-methionine diet. FASEB J, 28(2), 781–790. 10.1096/fj.13-240770 PubMed DOI PMC

Gupta S, Wang L, Anderl J, Slifker MJ, Kirk C, & Kruger WD (2013). Correction of cystathionine beta-synthase deficiency in mice by treatment with proteasome inhibitors. Hum Mutat, 34(8), 1085–1093. 10.1002/humu.22335 PubMed DOI PMC

Gupta S, Wang L, & Kruger WD (2017). The c.797 G>A (p.R266K) cystathionine beta-synthase mutation causes homocystinuria by affecting protein stability. Hum Mutat, 38(7), 863–869. 10.1002/humu.23240 PubMed DOI PMC

Hadi HA, Carr CS, & Al Suwaidi J (2005). Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag, 1(3), 183–198. https://www.ncbi.nlm.nih.gov/pubmed/17319104 PubMed PMC

Isabella VM, Ha BN, Castillo MJ, Lubkowicz DJ, Rowe SE, Millet YA, Anderson CL, Li N, Fisher AB, West KA, Reeder PJ, Momin MM, Bergeron CG, Guilmain SE, Miller PF, Kurtz CB, & Falb D (2018). Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat Biotechnol, 36(9), 857–864. 10.1038/nbt.4222 PubMed DOI

Ito S, Nakamura T, & Eguchi Y (1976). Purification and characterization of methioninase from Pseudomonas putida. J Biochem, 79(6), 1263–1272. 10.1093/oxfordjournals.jbchem.a131180 PubMed DOI

Jakubowski H (2020). Proteomic exploration of cystathionine beta-synthase deficiency: implications for the clinic. Expert Rev Proteomics, 17(10), 751–765. 10.1080/14789450.2020.1865160 PubMed DOI

James SJ, Melnyk S, Pogribna M, Pogribny IP, & Caudill MA (2002). Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr, 132(8 Suppl), 2361S–2366S. 10.1093/jn/132.8.2361S PubMed DOI

Keller R, Chrastina P, Pavlikova M, Gouveia S, Ribes A, Kolker S, Blom HJ, Baumgartner MR, Bartl J, Dionisi-Vici C, Gleich F, Morris AA, Kozich V, Huemer M, individual contributors of the European, N., Registry for, H., Methylation D, Baric I, Ben-Omran T, … Zeyda M (2019). Newborn screening for homocystinurias: Recent recommendations versus current practice. J Inherit Metab Dis, 42(1), 128–139. 10.1002/jimd.12034 PubMed DOI

Kennedy BP, Bottiglieri T, Arning E, Ziegler MG, Hansen LA, & Masliah E (2004). Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function. J Neural Transm (Vienna), 111(4), 547–567. 10.1007/s00702-003-0096-5 PubMed DOI

Kim D, & Li GC (1999). Proteasome inhibitors lactacystin and MG132 inhibit the dephosphorylation of HSF1 after heat shock and suppress thermal induction of heat shock gene expression. Biochem Biophys Res Commun, 264(2), 352–358. 10.1006/bbrc.1999.1371 PubMed DOI

Kopecka J, Krijt J, Rakova K, & Kozich V (2011). Restoring assembly and activity of cystathionine beta-synthase mutants by ligands and chemical chaperones. J Inherit Metab Dis, 34(1), 39–48. 10.1007/s10545-010-9087-5 PubMed DOI PMC

Kožich V, Schwahn B, Sokolová J, Křížková M, Ditroi T, Krijt J, Khalil Y, Křížek T, Vaculíková-Fantlová T, Stibůrková B, Mills P, Clayton P, Barvíková K, Blessing H, Sykut-Cegielska J, Dionisi-Vici C, Gasperini S, Garcia Cazorla A, Haack T, … Nagy P (2022). Human ultrarare genetic disorders of sulfur metabolism demonstrate redundancies in H2S homeostasis. Redox Biol. 10.1016/j.redox.2022.102517 PubMed DOI PMC

Kozich V, Sokolova J, Klatovska V, Krijt J, Janosik M, Jelinek K, & Kraus JP (2010). Cystathionine beta-synthase mutations: effect of mutation topology on folding and activity [Research Support, Non-U.S. Gov’t]. Hum Mutat, 31(7), 809–819. 10.1002/humu.21273 PubMed DOI PMC

Kozich V, Sokolova J, Morris AAM, Pavlikova M, Gleich F, Kolker S, Krijt J, Dionisi-Vici C, Baumgartner MR, Blom HJ, Huemer M, & consortium EH (2021). Cystathionine beta-synthase deficiency in the E-HOD registry-part I: pyridoxine responsiveness as a determinant of biochemical and clinical phenotype at diagnosis. J Inherit Metab Dis, 44(3), 677–692. 10.1002/jimd.12338 PubMed DOI PMC

Kozich V, & Stabler S (2020). Lessons Learned from Inherited Metabolic Disorders of Sulfur-Containing Amino Acids Metabolism. J Nutr, 150(Suppl 1), 2506S–2517S. 10.1093/jn/nxaa134 PubMed DOI

Kuzmin DA, Shutova MV, Johnston NR, Smith OP, Fedorin VV, Kukushkin YS, van der Loo JCM, & Johnstone EC (2021). The clinical landscape for AAV gene therapies. Nat Rev Drug Discov, 20(3), 173–174. 10.1038/d41573-021-00017-7 PubMed DOI

Lee DH, & Goldberg AL (1998). Proteasome inhibitors cause induction of heat shock proteins and trehalose, which together confer thermotolerance in Saccharomyces cerevisiae. Mol Cell Biol, 18(1), 30–38. 10.1128/MCB.18.1.30 PubMed DOI PMC

Lee HO, Gallego-Villar L, Grisch-Chan HM, Haberle J, Thony B, & Kruger WD (2019). Treatment of Cystathionine beta-Synthase Deficiency in Mice Using a Minicircle-Based Naked DNA Vector. Hum Gene Ther, 30(9), 1093–1100. 10.1089/hum.2019.014 PubMed DOI PMC

Lee HO, Salami CO, Sondhi D, Kaminsky SM, Crystal RG, & Kruger WD (2021). Long-term functional correction of cystathionine beta-synthase deficiency in mice by adeno-associated viral gene therapy. J Inherit Metab Dis, 44(6), 1382–1392. 10.1002/jimd.12437 PubMed DOI PMC

Levy HL, Thomas J, Ficicioglu C, Lah M, Ganesh J, Sellos-Moura M, Bublil EM, Wilkening L, Guner J, Chen Y, Greblikas F, & Vaidya SA (2022). Pegtibatinase, an investigational enzyme replacement therapy for the treatment of classical homocystinuria: Initial results from the Phase 1/2 COMPOSE study. 43rd Annual Meeting of the Society for Inherited Metabolic Disorders, Orlando, FL, USA.

Maclean KN, Sikora J, Kozich V, Jiang H, Greiner LS, Kraus E, Krijt J, Overdier KH, Collard R, Brodsky GL, Meltesen L, Crnic LS, Allen RH, Stabler SP, Elleder M, Rozen R, Patterson D, & Kraus JP (2010). A novel transgenic mouse model of CBS-deficient homocystinuria does not incur hepatic steatosis or fibrosis and exhibits a hypercoagulative phenotype that is ameliorated by betaine treatment [Research Support, N.I.H., Extramural]. Molecular Genetics and Metabolism, 101(2–3), 153–162. 10.1016/j.ymgme.2010.06.010 PubMed DOI PMC

Majors AK, & Pyeritz RE (2000). A deficiency of cysteine impairs fibrillin-1 deposition: implications for the pathogenesis of cystathionine beta-synthase deficiency. Mol Genet Metab, 70(4), 252–260. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10993712 PubMed

Majtan T, Bublil EM, Park I, Arning E, Bottiglieri T, Glavin F, & Kraus JP (2018). Pharmacokinetics and pharmacodynamics of PEGylated truncated human cystathionine beta-synthase for treatment of homocystinuria. Life Sci, 200, 15–25. 10.1016/j.lfs.2018.03.018 PubMed DOI

Majtan T, Hulkova H, Park I, Krijt J, Kozich V, Bublil EM, & Kraus JP (2017). Enzyme replacement prevents neonatal death, liver damage, and osteoporosis in murine homocystinuria. FASEB J, 31(12), 5495–5506. 10.1096/fj.201700565R PubMed DOI PMC

Majtan T, Jones W Jr., Krijt J, Park I, Kruger WD, Kozich V, Bassnett S, Bublil EM, & Kraus JP (2018). Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria. Mol Ther, 26(3), 834–844. 10.1016/j.ymthe.2017.12.014 PubMed DOI PMC

Majtan T, Krijt J, Sokolova J, Krizkova M, Ralat MA, Kent J, Gregory JF 3rd, Kozich V, & Kraus JP (2018). Biogenesis of Hydrogen Sulfide and Thioethers by Cystathionine Beta-Synthase. Antioxid Redox Signal, 28(4), 311–323. 10.1089/ars.2017.7009 PubMed DOI

Majtan T, Liu L, Carpenter JF, & Kraus JP (2010). Rescue of cystathionine beta-synthase (CBS) mutants with chemical chaperones: purification and characterization of eight CBS mutant enzymes [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. The Journal of biological chemistry, 285(21), 15866–15873. 10.1074/jbc.M110.107722 PubMed DOI PMC

Majtan T, Park I, Bublil EM, & Kraus JP (2018). Enzyme replacement therapy prevents loss of bone and fat mass in murine homocystinuria. Hum Mutat, 39(2), 210–218. 10.1002/humu.23360 PubMed DOI

Majtan T, Park I, Carrillo RS, Bublil EM, & Kraus JP (2017). Engineering and Characterization of an Enzyme Replacement Therapy for Classical Homocystinuria. Biomacromolecules, 18(6), 1747–1761. 10.1021/acs.biomac.7b00154 PubMed DOI

Majtan T, Park I, Cox A, Branchford BR, di Paola J, Bublil EM, & Kraus JP (2019). Behavior, body composition, and vascular phenotype of homocystinuric mice on methionine-restricted diet or enzyme replacement therapy. FASEB J, 33(11), 12477–12486. 10.1096/fj.201901203R PubMed DOI PMC

Majtan T, Pey AL, Ereno-Orbea J, Martinez-Cruz LA, & Kraus JP (2016). Targeting Cystathionine Beta-Synthase Misfolding in Homocystinuria by Small Ligands: State of the Art and Future Directions. Curr Drug Targets, 17(13), 1455–1470. http://www.ncbi.nlm.nih.gov/pubmed/26931358 PubMed

Majtan T, Pey AL, & Kraus JP (2016). Kinetic stability of cystathionine beta-synthase can be modulated by structural analogs of S-adenosylmethionine: Potential approach to pharmacological chaperone therapy for homocystinuria. Biochimie, 126, 6–13. 10.1016/j.biochi.2016.01.009 PubMed DOI

Majtan T, Singh LR, Wang L, Kruger WD, & Kraus JP (2008). Active cystathionine beta-synthase can be expressed in heme-free systems in the presence of metal-substituted porphyrins or a chemical chaperone [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. The Journal of biological chemistry, 283(50), 34588–34595. 10.1074/jbc.M805928200 PubMed DOI PMC

McCully KS (2009). Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Ann Clin Lab Sci, 39(3), 219–232. https://www.ncbi.nlm.nih.gov/pubmed/19667406 PubMed

Melenovska P, Kopecka J, Krijt J, Hnizda A, Rakova K, Janosik M, Wilcken B, & Kozich V (2015). Chaperone therapy for homocystinuria: the rescue of CBS mutations by heme arginate. J Inherit Metab Dis, 38(2), 287–294. 10.1007/s10545-014-9781-9 PubMed DOI

Morris AA, Kozich V, Santra S, Andria G, Ben-Omran TI, Chakrapani AB, Crushell E, Henderson MJ, Hochuli M, Huemer M, Janssen MC, Maillot F, Mayne PD, McNulty J, Morrison TM, Ogier H, O’Sullivan S, Pavlikova M, de Almeida IT, … Chapman KA (2017). Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis, 40(1), 49–74. 10.1007/s10545-016-9979-0 PubMed DOI PMC

Morrison T, Bosch F, Landolt MA, Kozich V, Huemer M, & Morris AAM (2021). Homocystinuria patient and caregiver survey: experiences of diagnosis and patient satisfaction. Orphanet J Rare Dis, 16(1), 124. 10.1186/s13023-021-01764-x PubMed DOI PMC

Mudd SH, Finkelstein JD, Irreverre F, & Laster L (1964). Homocystinuria: An enzymatic defect. Science, 143, 1443–1445. PubMed

Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, & Schweitzer L (1985). The natural history of homocystinuria due to cystathionine b-synthase deficiency. American Journal of Human Genetics, 37, 1–31. PubMed PMC

Mutze U, Gleich F, Garbade SF, Plisson C, Aldamiz-Echevarria L, Arrieta F, Ballhausen D, Zielonka M, Petkovic Ramadza D, Baumgartner MR, Cano A, Garcia Jimenez MC, Dionisi-Vici C, Jesina P, Blom HJ, Couce ML, Meavilla Olivas S, Mention K, Mochel F, … Kolker S (2022). Postauthorization safety study of betaine anhydrous. J Inherit Metab Dis, 45(4), 719–733. 10.1002/jimd.12499 PubMed DOI

Nguyen GN, Everett JK, Kafle S, Roche AM, Raymond HE, Leiby J, Wood C, Assenmacher CA, Merricks EP, Long CT, Kazazian HH, Nichols TC, Bushman FD, & Sabatino DE (2021). A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol, 39(1), 47–55. 10.1038/s41587-020-0741-7 PubMed DOI PMC

Niu W, Wu P, Chen F, Wang J, Shang X, & Xu C (2017). Discovery of selective cystathionine beta-synthase inhibitors by high-throughput screening with a fluorescent thiol probe. Medchemcomm, 8(1), 198–201. 10.1039/c6md00493h PubMed DOI PMC

Orlowski RZ, & Kuhn DJ (2008). Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res, 14(6), 1649–1657. 10.1158/1078-0432.CCR-07-2218 PubMed DOI

Pajares MA, & Perez-Sala D (2006). Betaine homocysteine S-methyltransferase: just a regulator of homocysteine metabolism? Cell Mol Life Sci, 63(23), 2792–2803. 10.1007/s00018-006-6249-6 PubMed DOI PMC

Panagaki T, Randi EB, Augsburger F, & Szabo C (2019). Overproduction of H2S, generated by CBS, inhibits mitochondrial Complex IV and suppresses oxidative phosphorylation in Down syndrome. Proc Natl Acad Sci U S A, 116(38), 18769–18771. 10.1073/pnas.1911895116 PubMed DOI PMC

Park ES, Oh HJ, Kruger WD, Jung SC, & Lee JS (2006). Recombinant adeno-associated virus mediated gene transfer in a mouse model for homocystinuria. Exp Mol Med, 38(6), 652–661. 10.1038/emm.2006.77 PubMed DOI

Park I, Bublil EM, Glavin F, & Majtan T (2020). Interplay of Enzyme Therapy and Dietary Management of Murine Homocystinuria. Nutrients, 12(9). 10.3390/nu12092895 PubMed DOI PMC

Park I, Hulkova H, Krijt J, Kozich V, Bublil EM, & Majtan T (2020). Long-term uninterrupted enzyme replacement therapy prevents liver disease in murine model of severe homocystinuria. Hum Mutat. 10.1002/humu.24072 PubMed DOI

Perla-Kajan J, Twardowski T, & Jakubowski H (2007). Mechanisms of homocysteine toxicity in humans. Amino Acids, 32(4), 561–572. 10.1007/s00726-006-0432-9 PubMed DOI

Perla-Kajan J, Utyro O, Rusek M, Malinowska A, Sitkiewicz E, & Jakubowski H (2016). N-Homocysteinylation impairs collagen cross-linking in cystathionine beta-synthase-deficient mice: a novel mechanism of connective tissue abnormalities. FASEB J, 30(11), 3810–3821. 10.1096/fj.201600539 PubMed DOI

Perreault M, Means J, Gerson E, Lee D, Horvath N, Rajasuriyar A, Moore T, Castillo M, Reeves A, & Hava D (2021). Development of an investigational methionine-consuming synthetic biotic medicine (SYNB1353) for the treatment of homocystinuria. 14th International Congress of Inborn Errors of Metabolism, Sydney, Australia.

Petrosino M, Zuhra K, Kopec J, Hutchin A, Szabo C, & Majtan T (2022). H2S biogenesis by cystathionine beta-synthase: mechanism of inhibition by aminooxyacetic acid and unexpected role of serine. Cell Mol Life Sci, 79(8), 438. 10.1007/s00018-022-04479-9 PubMed DOI PMC

Pey AL, Majtan T, Sanchez-Ruiz JM, & Kraus JP (2013). Human cystathionine beta-synthase (CBS) contains two classes of binding sites for S-adenosylmethionine (SAM): complex regulation of CBS activity and stability by SAM [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Biochem J, 449(1), 109–121. 10.1042/BJ20120731 PubMed DOI

Puurunen MK, Vockley J, Searle SL, Sacharow SJ, Phillips JA 3rd, Denney WS, Goodlett BD, Wagner DA, Blankstein L, Castillo MJ, Charbonneau MR, Isabella VM, Sethuraman VV, Riese RJ, Kurtz CB, & Brennan AM (2021). Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. Nat Metab, 3(8), 1125–1132. 10.1038/s42255-021-00430-7 PubMed DOI

Rasmussen K, & Moller J (2000). Total homocysteine measurement in clinical practice. Ann Clin Biochem, 37 (Pt 5), 627–648. http://www.ncbi.nlm.nih.gov/pubmed/11026516 PubMed

Sauls DL, Lockhart E, Warren ME, Lenkowski A, Wilhelm SE, & Hoffman M (2006). Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry, 45(8), 2480–2487. 10.1021/bi052076j PubMed DOI

Shayman JA, & Larsen SD (2014). The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases. J Lipid Res, 55(7), 1215–1225. 10.1194/jlr.R047167 PubMed DOI PMC

Singh LR, Chen X, Kozich V, & Kruger WD (2007). Chemical chaperone rescue of mutant human cystathionine beta-synthase. Mol Genet Metab, 91(4), 335–342. https://doi.org/S1096-7192(07)00136-9 [pii] 10.1016/j.ymgme.2007.04.011 PubMed DOI PMC

Singh LR, Gupta S, Honig NH, Kraus JP, & Kruger WD (2010). Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. PLoS Genet, 6(1), e1000807. 10.1371/journal.pgen.1000807 PubMed DOI PMC

Skovby F, Gaustadnes M, & Mudd SH (2010). A revisit to the natural history of homocystinuria due to cystathionine β-synthase deficiency. Molecular Genetics and Metabolism, 99(1), 1–3. 10.1016/j.ymgme.2009.09.009 PubMed DOI PMC

Skvorak K, Mitchell V, Teadt L, McCluskie K, Kruse N, Hunt S, Chang R, Pang L, Franklin K, Galanie S, Lee HO, Kruger WD, Thomas T, Hang J, Silverman A, Alaoui H, & Huisman G (2021). Discovery of CDX-6512, a gastrointestinal-stable methionine-gamma-lyase as a potential orally-administered enzyme therapy for homocystinuria. 14th International Congress of Inborn Errors of Metabolism, Sydney, Australia.

Stach K, Stach W, & Augoff K (2021). Vitamin B6 in Health and Disease. Nutrients, 13(9). 10.3390/nu13093229 PubMed DOI PMC

Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, & Cooper DN (2003). Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat, 21(6), 577–581. 10.1002/humu.10212 PubMed DOI

Stone E, Paley O, Hu J, Ekerdt B, Cheung NK, & Georgiou G (2012). De novo engineering of a human cystathionine-gamma-lyase for systemic (L)-Methionine depletion cancer therapy. ACS Chem Biol, 7(11), 1822–1829. 10.1021/cb300335j PubMed DOI PMC

Street TO, Bolen DW, & Rose GD (2006). A molecular mechanism for osmolyte-induced protein stability. Proc Natl Acad Sci U S A, 103(38), 13997–14002. 10.1073/pnas.0606236103 PubMed DOI PMC

Sun S, Weile J, Verby M, Wu Y, Wang Y, Cote AG, Fotiadou I, Kitaygorodsky J, Vidal M, Rine J, Jesina P, Kozich V, & Roth FP (2020). A proactive genotype-to-patient-phenotype map for cystathionine beta-synthase. Genome Med, 12(1), 13. 10.1186/s13073-020-0711-1 PubMed DOI PMC

Sun X, Yang Z, Li S, Tan Y, Zhang N, Wang X, Yagi S, Yoshioka T, Takimoto A, Mitsushima K, Suginaka A, Frenkel EP, & Hoffman RM (2003). In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5’-phosphate supplementation. Cancer Res, 63(23), 8377–8383. https://www.ncbi.nlm.nih.gov/pubmed/14678999 PubMed

Szabo C, Coletta C, Chao C, Modis K, Szczesny B, Papapetropoulos A, & Hellmich MR (2013). Tumor-derived hydrogen sulfide, produced by cystathionine-beta-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc Natl Acad Sci U S A, 110(30), 12474–12479. 10.1073/pnas.1306241110 PubMed DOI PMC

Thorson MK, Majtan T, Kraus JP, & Barrios AM (2013). Identification of Cystathionine beta-Synthase Inhibitors Using a Hydrogen Sulfide Selective Probe. Angew Chem Int Ed Engl, 52(17), 4641–4644. 10.1002/anie.201300841 PubMed DOI

Tran ML, Genisson Y, Ballereau S, & Dehoux C (2020). Second-Generation Pharmacological Chaperones: Beyond Inhibitors. Molecules, 25(14). 10.3390/molecules25143145 PubMed DOI PMC

Turner B (1967). Pyridoxine treatment in homocystinuria. Lancet, 2(7526), 1151. 10.1016/s0140-6736(67)90662-9 PubMed DOI

Wang D, Tai PWL, & Gao G (2019). Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov, 18(5), 358–378. 10.1038/s41573-019-0012-9 PubMed DOI PMC

Wang L, Chen X, Tang B, Hua X, Klein-Szanto A, & Kruger WD (2005). Expression of mutant human cystathionine beta-synthase rescues neonatal lethality but not homocystinuria in a mouse model [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. Hum Mol Genet, 14(15), 2201–2208. 10.1093/hmg/ddi224 PubMed DOI PMC

Weber Hoss GR, Sperb-Ludwig F, Schwartz IVD, & Blom HJ (2020). Classical homocystinuria: A common inborn error of metabolism? An epidemiological study based on genetic databases. Mol Genet Genomic Med, 8(6), e1214. 10.1002/mgg3.1214 PubMed DOI PMC

Yap S, & Naughten E (1998). Homocystinuria due to cystathionine beta-synthase deficiency in Ireland - 25 years experience of a newborn screened and treated population with reference to clinical outcome and biochemical control. Journal of Inherited Metabolic Disease, 21, 738–747. PubMed

Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, Parlati F, Ring E, Shenk KD, Shields J, Shwonek PJ, Stanton T, … Yang J (2009). Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem, 52(9), 3028–3038. 10.1021/jm801329v PubMed DOI

Zuhra K, Augsburger F, Majtan T, & Szabo C (2020). Cystathionine-beta-Synthase: Molecular Regulation and Pharmacological Inhibition. Biomolecules, 10(5). 10.3390/biom10050697 PubMed DOI PMC

Deciphering pathophysiological mechanisms underlying cystathionine beta-synthase-deficient homocystinuria using targeted metabolomics, liver proteomics, sphingolipidomics and analysis of mitochondrial function